scPharmaceuticals Inc
NASDAQ:SCPH
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
scPharmaceuticals Inc
NASDAQ:SCPH
|
US |
|
ValueCommerce Co Ltd
TSE:2491
|
JP |
|
G
|
Gold&S Co Ltd
KOSDAQ:035290
|
KR |
|
C
|
Currie Rose Resources Inc
XTSX:CUI
|
CA |
|
Maruwa Co Ltd
LSE:MAW
|
JP |
|
Ohsho Food Service Corp
TSE:9936
|
JP |
scPharmaceuticals Inc
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
scPharmaceuticals, Inc. engages in the development of transformative pharmaceutical products for subcutaneous delivery. The company is headquartered in Burlington, Massachusetts and currently employs 26 full-time employees. The company went IPO on 2017-11-17. The firm is focused on exploring, developing and commercializing products that expand and advance the outpatient care of acute conditions, including worsening heart failure and bacterial infections requiring outpatient parenteral antimicrobial therapy. Its lead product candidate, FUROSCIX, consists of its formulation of furosemide delivered via an on-body infusor and is under development for treatment of congestion in patients with heart failure who display reduced responsiveness to oral diuretics and do not require hospitalization. Its area of focus is congestion in heart failure and outpatient parenteral antimicrobial therapy (OPAT). Its pipeline programs include FUROSCIX, scCeftriaxone and scCarbapenem. Its FUROSCIX On-Body Infusor is a drug-device combination product consisting of FUROSCIX. The firm's wholly owned subsidiary is scPharmaceuticals Securities Corporation.
Revenue Growth: Net revenue reached $16 million in Q2 2025, up 99% from Q2 2024, driven by strong FUROSCIX demand.
FUROSCIX Uptake: Approximately 20,200 doses filled in Q2, a 117% year-over-year increase and 45% above Q1 2025, with rapid adoption in both cardiology and newly launched nephrology segments.
Nephrology Launch: Uptake in nephrology outpaced early cardiology adoption, with higher doses per prescription, and expected to become a meaningful contributor in Q3 and beyond.
IDN Channel Expansion: IDN sales grew 70% sequentially and are becoming a significant, though lumpy, part of total sales.
Medicare Dynamics: Medicare Part D redesign and patients hitting out-of-pocket maximums are now a tailwind for growth, reducing co-pays and boosting prescription volumes.
Cash Position: Ended Q2 with $40.8 million in cash and equivalents; management expects quarterly cash outflows to decrease as revenues grow.
Cost & Pricing: Anticipates a gross-to-net discount approaching 30% in Q3 and a 3.5% price increase effective July 1, 2025.
